RecruitingNot ApplicableNCT02978521

Pulmonary Rehabilitation in Advanced Non-small Cell Lung Cancer Patients

Effect of a Pulmonary Rehabilitation Program on Skeletal Muscle Mass, Pulmonary Function, Inflammatory Response and Overall Survival on Patients Diagnosed With Non-small-cell Advanced Cancer

Sponsor

Instituto Nacional de Cancerologia de Mexico

Enrollment

94 participants

Start Date

Aug 5, 2016

Study Type

INTERVENTIONAL

Conditions

Sarcopenia Quality of Life Pulmonary Rehabilitation

Summary

Lung cancer (LC) is usually diagnosed in advanced stages and continues to be the leading cause of cancer related deaths worldwide. Cancer cachexia are frequent among patients with LC affecting up to 80% of patients with advanced stage disease, and it has been related with higher risk of complications, length of hospital stay, and worst overall survival. During cancer cachexia, both muscle and fat mass can be wasted, however, the loss of muscle mass has been associated to higher treatment related toxicity, loss of functional status, shorter progression free survival and overall survival in different types of cancer under various treatments. Hence, preservation of muscle mass and function should be an important focus of the multidisciplinary treatment of patients with LC. Pulmonary rehabilitation (PR) has been known to improve pulmonary function, reduce fatigue and improve exercise tolerance in patients with LC undergoing curative surgery. However, few studies have focused on the efficacy of PR on patients with advanced cancer undergoing palliative care with chemotherapy or targeted therapies.

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether a structured exercise and breathing program (pulmonary rehabilitation) can improve quality of life and physical fitness in patients with advanced lung cancer who are also receiving cancer treatment. **You may be eligible if...** - You have been diagnosed with advanced non-small cell lung cancer (a common type of lung cancer) - Your general health is good (ECOG score 0 or 1 — meaning you are active and able to care for yourself) - Your life expectancy is more than 12 weeks - You are eligible to receive chemotherapy or targeted therapy (tyrosine kinase inhibitors) - You have had a recent normal electrocardiogram (heart tracing) **You may NOT be eligible if...** - You have brain metastases causing symptoms - Your pain is not well controlled - Your blood pressure is uncontrolled (above 140/100 mmHg) - You already do moderate to intense exercise regularly (3 or more days per week) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERPulmonary rehabilitation

Session 1: ventilatory pattern training Session 2,3: ventilatory pattern + respiratory training with incentive spirometer Session 4-6: Sessions 1-3 training continues + training with Positive expiratory pressure device (Threshold PEP) and breathing trainer Threshold IMT) Sessions 7-9: Continue respiratory training + resistance training with RECK MOTOmed2 ergometer at a 30% intensity until 60% is achieved Session 10-12: Continue with previous training + treadmill training